Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma

Blood. 2015 Sep 10;126(11):1394-7. doi: 10.1182/blood-2015-07-660365. Epub 2015 Jul 30.

Authors

Marta Celegato¹, Cinzia Borghese¹, Naike Casagrande¹, Maurizio Mongiat¹, Xaver U Kahle², Alice Paulitti¹, Michele Spina³, Alfonso Colombatti¹, Donatella Aldinucci¹

Affiliations

¹ Department of Experimental Oncology 2, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
² Department of Pathology and Medical Biology, University of Groningen, Groningen, The Netherlands.
³ Division of Medical Oncology A, CRO Aviano National Cancer Institute, Aviano, PN, Italy.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects
Auranofin / therapeutic use*
Cell Line, Tumor
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
Female
Hodgkin Disease / drug therapy*
Hodgkin Disease / metabolism
Hodgkin Disease / pathology
Humans
Mice
Mice, Nude
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents
Auranofin